![](/media/vdqhqzem/salmon.png)
Uppsala Reports editor
@UMCGlobalSafety
Real-world data is a rich source of evidence for pharmacovigilance, but there are challenges yet to be faced before unlocking its true potential as a resource.
Real-world data, or observational data collected during routine clinical care, could be a valuable source of evidence in pharmacovigilance. However, there are still hurdles to overcome before it can deliver on that value.
In the latest episode of the Drug Safety Matters podcast, Federica Santoro and Patrick Ryan from Johnson & Johnson discuss the challenges of using real-world data for patient safety and how this resource may be harnessed for pharmacovigilance through some ‘proof of concept’ projects such as OHDSI and EHDEN.
Like what you hear? Then subscribe to the podcast by visiting the Drug Safety Matters website.
When it comes to pharmacovigilance in older patients, age alone is insufficient as a measure of adverse reaction risk. Here is what we should consider instead.
Research / 13 May 2024
The traditional “drug-event combination” approach is too simplistic for complex side effects such as behavioural changes. We must adjust our methodology to address this intricacy.
Research / 29 May 2024
Adverse effects to medicines are not just physical in nature, but can manifest as behavioural side-effects too. How do we diagnose and treat these complex ADRs?
Research / 02 May 2024